Literature DB >> 26475337

[Operative therapy and irradiation of conjunctival melanoma].

H Westekemper1, D Meller2, R Darawsha2, S L Scholz2, D Flühs3, K-P Steuhl2, J Hérault4, J Thariat4, W Sauerwein3.   

Abstract

BACKGROUND: Radiotherapy of conjunctival melanoma has gained in importance in recent years compared to less invasive therapeutic approaches. This is due to the high recurrence rates achieved by omitting adjuvant therapy and to the increasing availability of suitable radiotherapeutic methods, so that tumors formerly not amenable to organ-preserving therapy can now be treated.
OBJECTIVE: This article presents the current radiotherapeutic options for conjunctival melanoma. The aim is to describe the diagnostic and therapeutic strategies and the course of therapy of malignant conjunctival melanoma. It is the authors' intention to justify the necessity of the adjuvant therapy of conjunctival melanoma and to emphasize the need for interdisciplinary cooperation during the course of tumor therapy.
METHODS: The article is based on results published in the literature as well as on data collected and experience gained in our centre.

Entities:  

Keywords:  Adjuvant therapy; Brachytherapy; Conjunctival melanoma; Proton Radiotherapy; Radiation therapy

Mesh:

Year:  2015        PMID: 26475337     DOI: 10.1007/s00347-015-0147-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  25 in total

1.  Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: analysis of 60 cases.

Authors:  M Tunc; D H Char; B Crawford; T Miller
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

2.  Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study.

Authors:  Gerasimos Anastassiou; Arnd Heiligenhaus; Nikos Bechrakis; Elisabeth Bader; Norbert Bornfeld; Klaus-Peter Steuhl
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

3.  Current trends in the treatment of ocular melanoma by radiotherapy.

Authors:  John L Hungerford
Journal:  Clin Exp Ophthalmol       Date:  2003-02       Impact factor: 4.207

4.  Long-term follow-up of patients with conjunctival melanoma.

Authors:  Cornelia Werschnik; Peter K Lommatzsch
Journal:  Am J Clin Oncol       Date:  2002-06       Impact factor: 2.339

5.  Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience.

Authors:  Madhavi Kurli; Paul T Finger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-07       Impact factor: 3.117

6.  Conjunctival melanoma in the Netherlands: a nationwide study.

Authors:  Guy S Missotten; Sander Keijser; Rob J W De Keizer; Didi De Wolff-Rouendaal
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-01       Impact factor: 4.799

Review 7.  Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond.

Authors:  T Kivelä; E Kujala
Journal:  Eye (Lond)       Date:  2012-12-21       Impact factor: 3.775

8.  Plaque brachytherapy for the management of ocular surface malignancies with corneoscleral invasion.

Authors:  Natalie Walsh-Conway; R Max Conway
Journal:  Clin Exp Ophthalmol       Date:  2009-08       Impact factor: 4.207

Review 9.  Radiotherapy for ocular tumours.

Authors:  C Stannard; W Sauerwein; G Maree; K Lecuona
Journal:  Eye (Lond)       Date:  2012-11-23       Impact factor: 3.775

10.  Conjunctival melanoma: a review of conceptual and treatment advances.

Authors:  Li-Anne Lim; Michele C Madigan; R Max Conway
Journal:  Clin Ophthalmol       Date:  2013-03-13
View more
  2 in total

Review 1.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

Review 2.  Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights.

Authors:  Joel M Mor; Alexander C Rokohl; Konrad R Koch; Ludwig M Heindl
Journal:  Clin Ophthalmol       Date:  2019-07-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.